These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11458814)

  • 1. A phase I-II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3).
    Rinaldi D; Lormand N; Brierre J; Cole J; Barnes B; Fontenot F; Buller E; Rainey J
    Cancer Invest; 2001; 19(5):467-74. PubMed ID: 11458814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer.
    Dabrow MB; Francesco MR; Gilman PB; Cantor R; Rose L; Meyer TJ
    Cancer Invest; 2003; 21(4):517-25. PubMed ID: 14533441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer.
    Bidoli P; Stani SC; Mariani L; De Candis D; Cortinovis D; Aglione S; Zilembo N; Toffolatti L; Formisano B; Bajetta E
    Lung Cancer; 2004 Feb; 43(2):203-8. PubMed ID: 14739041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase II trial of topotecan and gemcitabine in patients with previously treated, advanced nonsmall cell lung carcinoma.
    Rinaldi DA; Lormand NA; Brierre JE; Cole JL; Barnes BC; Mills G; Yadlapati S; Felicia Fontenot M; Buller EJ; Rainey JM
    Cancer; 2002 Sep; 95(6):1274-8. PubMed ID: 12216095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie Study.
    Thomas P; Robinet G; Ferri-Dessens RM; Léna H; Gouva S; Vernejoux JM; Kleisbauer JP
    Lung Cancer; 2002 May; 36(2):191-8. PubMed ID: 11955654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.
    Gajra A; Mehdi SA; Kirshner J; Newman N; Graziano SL
    Lung Cancer; 2001 May; 32(2):189-96. PubMed ID: 11325490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose-escalation study of weekly topotecan, cisplatin, and gemcitabine front-line therapy in patients with inoperable non-small cell lung cancer.
    Guarino MJ; Schneider CJ; Grubbs SS; Biggs DD; Himelstein AL; Hogaboom K; Tilak S
    Oncologist; 2002; 7(6):509-15. PubMed ID: 12490738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl cancer research network phase II trial.
    Hainsworth JD; Burris HA; Litchy S; Erland JB; Hon JK; Brierre JE; Greco FA
    Cancer; 2000 Mar; 88(6):1353-8. PubMed ID: 10717616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of gemcitabine and infusional 5-fluorouracil (5-FU) in patients with refractory solid tumors: Louisiana Oncology Associates protocol no. 1 (LOA-1).
    Rinaldi DA; Lormand NA; Brierre JE; Cole JL; Stagg MP; Fontenot MF; Buller EJ; Rainey JM
    Am J Clin Oncol; 2000 Feb; 23(1):78-82. PubMed ID: 10683085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer.
    De Pas T; de Braud F; Danesi R; Sessa C; Catania C; Curigliano G; Fogli S; del Tacca M; Zampino G; Sbanotto A; Rocca A; Cinieri S; Marrocco E; Milani A; Goldhirsch A
    Ann Oncol; 2000 Jul; 11(7):821-7. PubMed ID: 10997809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer.
    Bajetta E; Stani SC; De Candis D; Zaffaroni N; Zilembo N; Cortinovis D; Aglione S; Mariani L; Formisano B; Bidoli P
    Ann Oncol; 2003 Feb; 14(2):242-7. PubMed ID: 12562651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer.
    Shepherd FA; Cormier Y; Burkes R; Evans WK; Goss G; Klimo P; Feld R; Taylor M
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-27-S8-30. PubMed ID: 9207313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer.
    Kurata T; Tamura K; Yamamoto N; Nogami T; Satoh T; Kaneda H; Nakagawa K; Fukuoka M
    Br J Cancer; 2004 Jun; 90(11):2092-6. PubMed ID: 15150564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.
    Spiridonidis CH; Laufman LR; Jones J; Rhodes VA; Wallace K; Nicol S
    J Clin Oncol; 1998 Dec; 16(12):3866-73. PubMed ID: 9850032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer.
    Iaffaioli RV; Tortoriello A; Facchini G; Caponigro F; Gentile M; Marzano N; Gravina A; Dimitri P; Costagliola G; Ferraro A; Ferrante G; De Marino V; Illiano A
    J Clin Oncol; 1999 Mar; 17(3):921-6. PubMed ID: 10071285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase I study.
    Athanasiadis A; Roussos G; Papakostoulis T; Athanasiadou DC; Stathopoulos GP
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):653-8. PubMed ID: 15937714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A phase I study of gemcitabine and irinotecan as second line treatment for advanced non-small cell lung cancer].
    Ryo H; Toyama K; Isobe K; Sugino K; Sano G; Yamada H; Hiroi M; Hojyo T; Kimura K
    Gan To Kagaku Ryoho; 2003 Feb; 30(2):237-42. PubMed ID: 12610872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma.
    Raymond E; Burris HA; Rowinsky EK; Eckardt JR; Rodriguez G; Smith L; Weiss G; Von Hoff DD
    Ann Oncol; 1997 Oct; 8(10):1003-8. PubMed ID: 9402174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
    Davies AM; Ruel C; Lara PN; Lau DH; Gumerlock PH; Bold R; Shibata S; Lenz HJ; Schenkein DP; Gandara DR
    J Thorac Oncol; 2008 Jan; 3(1):68-74. PubMed ID: 18166843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
    Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
    Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.